The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...
High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...
A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...
The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.
identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as do other candidates in the late-stage ...
Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Please note that sales of Pfizer’s PFE RSV vaccine, Abrysvo, and GSK plc’s GSK RSV vaccine Arexvy also declined in the fourth quarter. This downtick can be attributed to the restrictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback